{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:45:44Z","timestamp":1777956344016,"version":"3.51.4"},"reference-count":37,"publisher":"Universidad del Valle","issue":"1","license":[{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["colombiamedica.univalle.edu.co"],"crossmark-restriction":true},"short-container-title":["Colomb Med"],"abstract":"<jats:p>ObjetivoDescribir los desenlaces obst\u00e9tricos asociados al uso de dinoprostona y su efectividad en la maduraci\u00f3n cervical en gestantes con trastornos hipertensivos asociados al embarazo frente a gestantes normotensas.\nM\u00e9todosEstudio de cohorte retrospectivo en hospital de tercer nivel en Medell\u00edn, Colombia (marzo 2020 - octubre 2024). Se incluyeron gestantes con embarazo \u00fanico, mayores de 30 semanas, feto vivo en presentaci\u00f3n cef\u00e1lica y maduraci\u00f3n cervical con \u00f3vulo de dinoprostona. Se excluyeron mujeres con uso de otros m\u00e9todos de maduraci\u00f3n, c\u00e9rvix favorable al ingreso o trastorno hipertensivo no clasificado. Los desenlaces principales fueron maduraci\u00f3n cervical exitosa, parto vaginal, tiempos hasta Bishop favorable y parto, e indicaciones de ces\u00e1rea. Se consideraron eventos adversos como abrupcio placentario, estado fetal no tranquilizador, taquisistolia y empeoramiento hipertensivo\nResultados\nSe incluyeron 400 pacientes (200 hipertensas, de \u00e9stas, 100 con preeclampsia grave). La tasa de \u00e9xito en la maduraci\u00f3n cervical fue similar en pacientes con trastornos hipertensivos y mujeres sanas RR crudo 0.95, IC 95%: 0.88-1.03, RR ajustado por edad gestacional, edad materna y paridad 0.96, IC 95%: 0.88-1.04. La tasa de parto vaginal fue similar 44 y 55% (p: 0.16). La mediana de tiempo a Bishop favorable y al parto fue comparable entre normotensas e hipertensas, incluso en casos graves. La ces\u00e1rea se debi\u00f3 principalmente a maduraci\u00f3n fallida y decisi\u00f3n m\u00e9dica. Los eventos adversos, excepto la taquisistolia, fueron m\u00e1s frecuentes en hipertensas, sin significaci\u00f3n estad\u00edstica.\nConclusi\u00f3nLa dinoprostona es eficaz en pacientes hipertensas, incluso con uso de sulfato de magnesio, sin diferencias significativas frente a normotensas\n\u00a0<\/jats:p>","DOI":"10.25100\/cm.v56i1.6719","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T21:37:32Z","timestamp":1752097052000},"page":"e2016719","update-policy":"https:\/\/doi.org\/10.25100\/cm.crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Inducci\u00f3n del trabajo de parto con dinoprostona en trastornos hipertensivos del embarazo","Induction of labor with dinoprostone in hypertensive disorders of pregnancy"],"prefix":"10.25100","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4773-991X","authenticated-orcid":false,"given":"Laura Camila","family":"Molina-Barrera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-2513","authenticated-orcid":false,"given":"Mar\u00eda Sady","family":"Bustamante-De la Ossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5407-7714","authenticated-orcid":false,"given":"John Jairo","family":"Zuleta-Tob\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10728","published-online":{"date-parts":[[2025,3,30]]},"reference":[{"key":"94901","doi-asserted-by":"crossref","unstructured":"Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA, et al. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. Hypertension. 2022; 79(2): e21-41. Doi: 10.1161\/HYP.0000000000000208","DOI":"10.1161\/HYP.0000000000000208"},{"key":"94902","doi-asserted-by":"crossref","unstructured":"Instituto Nacional de Salud. Mortalidad. Bolet\u00edn epidemiol\u00f3gico. 2023; semana 52. Doi: 10.33610\/23576189.2023.52","DOI":"10.33610\/23576189.2023.52"},{"key":"94903","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists' Committee on Obstetric Practice, Society for Maternal-Fetal Medicine. Medically indicated late-preterm and early-term deliveries: ACOG Committee Opinion, Number 831. Obstet Gynecol. 2021; 138(1): e35-9. Doi: 10.1097\/AOG.0000000000004447","DOI":"10.1097\/AOG.0000000000004447"},{"key":"94904","doi-asserted-by":"crossref","unstructured":"Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222. Obstet Gynecol. 2020; 135(6): 1492-5. Doi: 10.1097\/AOG.0000000000003892","DOI":"10.1097\/AOG.0000000000003892"},{"key":"94905","doi-asserted-by":"crossref","unstructured":"Tsakiridis I, Giouleka S, Arvanitaki A, Giannakoulas G, Papazisis G, Mamopoulos A, et al. Gestational hypertension and preeclampsia: an overview of national and international guidelines. Obstet Gynecol Surv. 2021; 76(10): 613. Doi: 10.1097\/OGX.0000000000000942","DOI":"10.1097\/OGX.0000000000000942"},{"key":"94906","doi-asserted-by":"crossref","unstructured":"Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009; 374(9694): 979-88. Doi: 10.1016\/S0140-6736(09)60736-4.","DOI":"10.1016\/S0140-6736(09)60736-4"},{"key":"94907","doi-asserted-by":"crossref","unstructured":"Taliento C, Manservigi M, Tormen M, Cappadona R, Piccolotti I, Salvioli S, et al. Safety of misoprostol vs dinoprostone for induction of labor: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2023; 289: 108-28. Doi: 10.1016\/j.ejogrb.2023.08.382","DOI":"10.1016\/j.ejogrb.2023.08.382"},{"key":"94908","doi-asserted-by":"crossref","unstructured":"Grobman WA, Rice MM, Reddy UM, Tita ATN, Silver RM, Mallett G, et al. Labor Induction versus Expectant Management in Low-Risk Nulliparous Women. N Engl J Med. 2018; 379(6): 513-23. Doi: 10.1056\/NEJMoa1800566","DOI":"10.1056\/NEJMoa1800566"},{"key":"94909","doi-asserted-by":"crossref","unstructured":"de Paiva MRMC, Souza ASR, de Lucena FFE, da Costa AAR, Amorim MMR. Maternal and perinatal outcomes in women with and without hypertensive syndromes submitted to induction of labor with misoprostol. Hypertens Pregnancy. 2017; 36(1): 1-7. Doi: 10.1080\/10641955.2016.1197935","DOI":"10.1080\/10641955.2016.1197935"},{"key":"94910","doi-asserted-by":"crossref","unstructured":"Gofton EN, Capewell V, Natale R, Gratton RJ. Obstetrical intervention rates and maternal and neonatal outcomes of women with gestational hypertension. Am J Obstet Gynecol. 2001; 185(4): 798-803. Doi: 10.1067\/mob.2001.117314","DOI":"10.1067\/mob.2001.117314"},{"key":"94911","doi-asserted-by":"crossref","unstructured":"Gornisiewicz T, Huras H, Kusmierska-Urban K, Galas A. Pregnancy-related comorbidities and labor induction - the effectiveness and safety of dinoprostone compared to misoprostol. Ginekol Pol. 2021; 92(9): 647-58. Doi: 10.5603\/GP.a2021.0092","DOI":"10.5603\/GP.a2021.0092"},{"key":"94912","doi-asserted-by":"crossref","unstructured":"Xenakis EM, Piper JM, Field N, Conway D, Langer O. Preeclampsia: is induction of labor more successful? Obstet Gynecol. 1997; 89(4): 600-3. Doi: 10.1016\/S0029-7844(97)00043-4","DOI":"10.1016\/S0029-7844(97)00043-4"},{"key":"94913","doi-asserted-by":"crossref","unstructured":"Penfield CA, Nageotte MP, Wing DA. Disparate Rates of Cesarean Delivery in Term Nulliparous Women with Hypertensive Disorders of Pregnancy. Am J Perinatol. 2019; 36: 997-1001. Doi: 10.1055\/s-0039-1681057","DOI":"10.1055\/s-0039-1681057"},{"key":"94914","doi-asserted-by":"crossref","unstructured":"Hagans MJ, Stanhope KK, Boulet SL, Jamieson DJ, Platner MH. Delivery outcomes after induction of labor among women with hypertensive disorders of pregnancy. J Matern Fetal Neonatal Med. 2022; 35(25): 9215-21. Doi: 10.1080\/14767058.2021.2022645.","DOI":"10.1080\/14767058.2021.2022645"},{"key":"94915","doi-asserted-by":"crossref","unstructured":"Park KH, Cho YK, Lee CM, Choi H, Kim BR, Lee HK. Effect of Preeclampsia, Magnesium Sulfate Prophylaxis, and Maternal Weight on Labor Induction: A Retrospective Analysis. Gynecol Obstet Invest. 2006; 61(1): 40-4. Doi: 10.1159\/000088424.","DOI":"10.1159\/000088424"},{"key":"94916","doi-asserted-by":"crossref","unstructured":"Arrowsmith S, Neilson J, Wray S. The combination tocolytic effect of magnesium sulfate and an oxytocin receptor antagonist in myometrium from singleton and twin pregnancies. Am J Obstet Gynecol. 2016; 215(6): 789.e1-789.e9. Doi: 10.1016\/j.ajog.2016.08.015","DOI":"10.1016\/j.ajog.2016.08.015"},{"key":"94917","doi-asserted-by":"crossref","unstructured":"Mei JY, Lee D, Negi M. Duration of labor induction in nulliparous women receiving magnesium sulfate and maternal and neonatal outcomes. Am J Obstet Gynecol. 1 de enero de 2023;228(1):S662. Doi: 10.1016\/j.ajog.2022.11.1112","DOI":"10.1016\/j.ajog.2022.11.1112"},{"key":"94918","doi-asserted-by":"crossref","unstructured":"Sheibani L, Raymond K, Rugarn O, Wing DA. Associations of hypertensive disorders of pregnancy and outcomes of labor induction with prostaglandin vaginal inserts. Hypertens Pregnancy. 2018; 37(1): 51-7. Doi: 10.1080\/10641955.2017.1420800","DOI":"10.1080\/10641955.2017.1420800"},{"key":"94919","doi-asserted-by":"crossref","unstructured":"Gornisiewicz T, Kusmierska-Urban K, Huras H, Galas A. Comparison of Misoprostol versus Dinoprostone for delivery induction among pregnant women without concomitant disease. Ginekol Pol. 2020; 91(12): 726-32. Doi: 10.5603\/GP.2020.0119","DOI":"10.5603\/GP.2020.0119"},{"key":"94920","doi-asserted-by":"crossref","unstructured":"Robinson D, Campbell K, Hobson SR, MacDonald WK, Sawchuck D, Wagner B. Guideline No. 432a: Cervical Ripening and Induction of Labour - General Information. J Obstet Gynaecol Can. 2023; 45(1): 35-44.e1. Doi: 10.1016\/j.jogc.2022.11.005","DOI":"10.1016\/j.jogc.2022.11.005"},{"key":"94921","doi-asserted-by":"crossref","unstructured":"Sanchez-Ramos L, Levine LD, Sciscione AC, Mozurkewich EL, Ramsey PS, Adair CD, et al. Methods for the induction of labor: efficacy and safety. Am J Obstet Gynecol. 2024; 230(3): S669-95. Doi: 10.1016\/j.ajog.2023.02.009","DOI":"10.1016\/j.ajog.2023.02.009"},{"key":"94922","unstructured":"WHO Consultation on Obesity. Obesity: preventing and managing the global epidemic. report of a WHO consultation. World Health Organization; 2000. Citado: 25 de diciembre de 2024. Disponible en: https:\/\/iris.who.int\/handle\/10665\/42330"},{"key":"94923","doi-asserted-by":"crossref","unstructured":"Ananth CV, Schisterman EF. Confounding, causality, and confusion: the role of intermediate variables in interpreting observational studies in obstetrics. Am J Obstet Gynecol. 2017; 217(2): 167-75. Doi: 10.1016\/j.ajog.2017.04.016","DOI":"10.1016\/j.ajog.2017.04.016"},{"key":"94924","doi-asserted-by":"crossref","unstructured":"L\u00f3pez Jim\u00e9nez N, Garc\u00eda S\u00e1nchez F, Pailos RH, Rodrigo \u00c1lvaro V, Pascual Pedre\u00f1o A, Moreno Cid M, et al. Prediction of an effective cervical ripenning in the induction of labour using vaginal dinoprostone. Sci Rep. 2023; 13(1): 6855. Doi: 10.1038\/s41598-023-33974-7","DOI":"10.1038\/s41598-023-33974-7"},{"key":"94925","doi-asserted-by":"crossref","unstructured":"Chang TA, Li YR, Ding DC. Oxytocin and vaginal dinoprostone in labor induction: A systematic review and meta-analysis. Int J Gynecol Obstet. 2024; 166(2): 626-38. Doi: 10.1002\/ijgo.15443","DOI":"10.1002\/ijgo.15443"},{"key":"94926","doi-asserted-by":"crossref","unstructured":"Ca\u00f1adas JV, Gonz\u00e1lez MT, Lim\u00f3n NP, Alguacil MS, Prieto MGL, Riaza RC, et al. Intracervical double-balloon catheter versus dinoprostone for cervical ripening in labor induction in pregnancies with a high risk of uterine hyperstimulation. Arch Gynecol Obstet. 2021; 304(6): 1475-84. Doi: 10.1007\/s00404-021-06071-1","DOI":"10.1007\/s00404-021-06071-1"},{"key":"94927","doi-asserted-by":"crossref","unstructured":"Yan M, Li L, Wang J. Impact of dinoprostone versus cook cervical ripening balloon on induction in pregnancies complicated by small-for-gestational-age fetuses at term. J Matern Fetal Neonatal Med. 2024; 37(1): 2381584. Doi: 10.1080\/14767058.2024.2381584","DOI":"10.1080\/14767058.2024.2381584"},{"key":"94928","doi-asserted-by":"crossref","unstructured":"Levast F, Legendre G, Hachem HE, Saulnier P, Descamps P, Gillard P, et al. A mathematical model to predict mean time to delivery following cervical ripening with dinoprostone vaginal insert. Sci Rep. 2019; 9(1): 9910. Doi: 10.1038\/s41598-019-46101-2 PMid:31289277","DOI":"10.1038\/s41598-019-46101-2"},{"key":"94929","doi-asserted-by":"crossref","unstructured":"Wing DA, Brown R, Plante LA, Miller H, Rugarn O, Powers BL. Misoprostol Vaginal Insert and Time to Vaginal Delivery: A Randomized Controlled Trial. Obstet Gynecol. 2013; 122(2 PART 1): 201. Doi: 10.1097\/AOG.0b013e31829a2dd6","DOI":"10.1097\/AOG.0b013e31829a2dd6"},{"key":"94930","doi-asserted-by":"crossref","unstructured":"Lapaire O, Zanetti-D\u00e4llenbach R, Weber P, H\u00f6sli I, Holzgreve W, Surbek D. Labor induction in preeclampsia: Is misoprostol more effective than dinoprostone? 2007; 35(3): 195-9. Doi: 10.1515\/JPM.2007.028","DOI":"10.1515\/JPM.2007.028"},{"key":"94931","doi-asserted-by":"crossref","unstructured":"Huang F, Chen H, Wu X, Li J, Guo J, Zhang X, et al. A model to predict delivery time following induction of labor at term with a dinoprostone vaginal insert: a retrospective study. Ir J Med Sci. 2024; 193(3): 1343-50. Doi: 10.1007\/s11845-023-03568-3","DOI":"10.1007\/s11845-023-03568-3"},{"key":"94932","doi-asserted-by":"crossref","unstructured":"Wolfe KB, Rossi RA, Warshak CR. The effect of maternal obesity on the rate of failed induction of labor. Am J Obstet Gynecol. 2011; 205(2): 128.e1-128.e7. Doi: 10.1016\/j.ajog.2011.03.051","DOI":"10.1016\/j.ajog.2011.03.051"},{"key":"94933","doi-asserted-by":"crossref","unstructured":"Ellis JA, Brown CM, Barger B, Carlson NS. Influence of Maternal Obesity on Labor Induction: A Systematic Review and Meta-Analysis. J Midwifery Womens Health. 2019; 64(1): 55-67. Doi: 10.1111\/jmwh.12935","DOI":"10.1111\/jmwh.12935"},{"key":"94934","doi-asserted-by":"crossref","unstructured":"Yenuberi H, Mathews J, George A, Benjamin S, Rathore S, Tirkey R, et al. The efficacy and safety of 25 \u03bcg or 50 \u03bcg oral misoprostol versus 25 \u03bcg vaginal misoprostol given at 4- or 6-hourly intervals for induction of labour in women at or beyond term with live singleton pregnancies: A systematic review and meta-analysis. Int J Gynaecol Obstet. 2024; 164(2): 482-98. Doi: 10.1002\/ijgo.14970","DOI":"10.1002\/ijgo.14970"},{"key":"94935","doi-asserted-by":"crossref","unstructured":"Weeks AD, Lightly K, Mol BW, Frohlich J, Pontefract S, Williams MJ, et al. Evaluating misoprostol and mechanical methods for induction of labour: Scientific Impact Paper No. 68 April 2022. BJOG Int J Obstet Gynaecol. 2022; 129(8): e61-5. Doi: 10.1111\/1471-0528.17136","DOI":"10.1111\/1471-0528.17136"},{"key":"94936","doi-asserted-by":"crossref","unstructured":"Morikawa M, Cho K, Yamada T, Yamada T, Sato S, Minakami H. Do uterotonic drugs increase risk of abruptio placentae and eclampsia? Arch Gynecol Obstet. 2014; 289(5): 987-91. Doi: 10.1007\/s00404-013-3101-8","DOI":"10.1007\/s00404-013-3101-8"},{"key":"94937","doi-asserted-by":"crossref","unstructured":"Martinez de Tejada B, Martillotti G, Lapaire O, Hoesli I, Irion O. The risk of placental abruption when using prostaglandins for cervical ripening in women with preeclampsia: Comparing misoprostol versus dinoprostone. J Matern Fetal Neonatal Med. 2010; 23(9): 988-93. Doi: 10.3109\/14767050903443475","DOI":"10.3109\/14767050903443475"}],"container-title":["Colombia Medica"],"original-title":[],"link":[{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/download\/6719\/8330","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/download\/6719\/8323","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/download\/6719\/8337","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/download\/6719\/8330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:53:09Z","timestamp":1777945989000},"score":1,"resource":{"primary":{"URL":"https:\/\/colombiamedica.univalle.edu.co\/index.php\/comedica\/article\/view\/6719"}},"subtitle":["an\u00e1lisis comparativo con gestantes normotensas","comparative analysis with normotensive pregnant women"],"short-title":[],"issued":{"date-parts":[[2025,3,30]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,12]]}},"URL":"https:\/\/doi.org\/10.25100\/cm.v56i1.6719","relation":{},"ISSN":["1657-9534","0120-8322"],"issn-type":[{"value":"1657-9534","type":"electronic"},{"value":"0120-8322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,30]]},"assertion":[{"value":"Yes","name":"crosschecked","label":"CrossChecked"},{"value":"Yes","name":"peer_reviewed","label":"Peer Reviewed"},{"value":"2024-09-30","name":"published","label":"Published"}]}}